The purpose of this study to preliminarily evaluate the safety and efficacy of High Efficient Killing Cell Therapy for refractory and advanced non-small cell lung cancer

Patients with pathological confirmed non-small cell lung cancer with no standard treatment are enrolled. The patients fails in previous at least 2 lines of chemotherapy and 1 line of targeted therapy where applicable. This is a prospective exploratory trial.

Inclusion Criteria:

• Male or female patients' age from 18 years to 70 years.
• Patients who have a life expectancy of at least 3 months.
• pathologically confirmed non-small cell lung cancer.
• failed in previous standard chemotherapy and targeted therapy.
• Karnofsky performance status 0-1.
• adequate organ functions.

Exclusion Criteria:

• Pregnant and lactating women.
• Patients with T cell lymphoma, syphilis, AIDS or combination
• Patients with highly allergic or have a history of severe allergies
• Patients with severe hepatic or renal dysfunction
• Patients with severe autoimmune disease or who is being treated with immunosuppressive agents
• Patients with severe infection not controlled or High fever
• Patients with organ transplantation or waiting for organ transplantation.
• Patients with brain metastasis
• Patients with severe coagulopathy (e.g. hemophilia)
• Patients without adequate ability to understand, sign informed consents and take part in the clinical research voluntarily.